T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyFrancesco Schettini, Lucia Del Mastro, Sara Parola et al.|ESMO Open|2021Cited by 22
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancerFabio Puglisi, Lucia Del Mastro, Lorenzo Gerratana et al.|npj Breast Cancer|2021Cited by 9